Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 25, 2015 4:16 AM ET


Company Overview of Juventas Therapeutics, Inc.

Company Overview

Juventas Therapeutics, Inc. discovers and develops biopharmaceutical therapies for regenerative medicine. It offers Stromal Derived Factor-1, a therapy that improves cardiac function, as well as enables to protect and repair tissues following organ–damage in pre–clinical disease models. The company also develops biopharmaceuticals that activate the natural repair process that occurs after an injury. In addition, it provides therapies for wound healing and peripheral vascular diseases. Juventas Therapeutics, Inc. was formerly known as AcelleRX Therapeutics, Inc. and changed its name to Juventas Therapeutics, Inc. in April 2009. The company was founded in 2007 and is based in Cleveland, Ohio.

10265 Carnegie Avenue

Cleveland, OH 44106-2130

United States

Founded in 2007





Key Executives for Juventas Therapeutics, Inc.

Chief Executive officer, President and Director
Founder, Chairman of Scientific Advisory Board, Chief Scientific Officer and Chief Medical Officer
Chief Financial Officer
Age: 55
Senior Vice President of Finance & Operations
Age: 47
Chief Strategy Officer
Compensation as of Fiscal Year 2015.

Juventas Therapeutics, Inc. Key Developments

Juventas Therapeutics, Inc. Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-07-2015 02:15 PM

Juventas Therapeutics, Inc. Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-07-2015 02:15 PM. Venue: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037, United States. Speakers: Paul Resnick, Vice President of Business Development.

Juventas Therapeutics, Inc., Receives Fast Track Designation from the U.S. Food and Drug Administration on JVS-100

Juventas Therapeutics, Inc. announced that its product candidate, JVS-100, received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of advanced ischemic chronic heart failure. The FDA Fast Track process is designed toexpedite the development and review of drugs to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs. The FDA has also allowed the protocol for the company's Phase 2b double-blinded, randomized clinical trial of JVS-100 for the treatment of advanced ischemic chronic heart failure in patients with a prior history of heart attack, referred to as STOP-HF2. The STOP-HF2 trial is expected to enroll up to 180 patients at as many as 40 clinical centers in a double-blinded, 1:1 randomized, sham-controlled study evaluating the impact of two administrations of 30mg doses of JVS-100 in heart failure patients with low ejection fraction (less than or equal to 35%) and elevated serum biomarkers (NTproBNP greater than or equal to 500 pg/mL). The first dose will be delivered at the time of patient enrollment and the second will be delivered six months later, each by endomyocardial injection catheter to the left ventricle of the heart.

Juventas Therapeutics, Inc. Appoints James Boland as Independent Director

Juventas Therapeutics, Inc. expanded its Board of Directors to include James Boland as an independent director. Mr. Boland is the retired vice chairman of Ernst & Young and former president, chief executive officer and vice chairman of the Cleveland Cavaliers Operating Company. He currently serves as Chairman of JobsOhio and is on the Board of the Center for Global Business Studies in Washington D.C.

Similar Private Companies By Industry

Company Name Region
Caliber Therapeutics, Inc. United States
Nektar Therapeutics Al, Corp United States
W.F. Young, Inc. United States
TSI Health Sciences, Inc. United States
Maryland Progressive Health, LLC United States

Recent Private Companies Transactions

Private Placement
May 4, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Juventas Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at